Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases

Nkarta, Inc. ((NKTX)) announced an update on their ongoing clinical study.

Study Overview: Nkarta, Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases.’ The study aims to evaluate the safety and tolerability of NKX019 in participants with immune-mediated diseases such as systemic sclerosis, idiopathic inflammatory myopathies, and ANCA-associated vasculitis. This research is significant as it explores innovative therapies for conditions with limited treatment options.

Intervention/Treatment: The study tests NKX019, an investigational allogeneic CD19-directed CAR NK cell therapy, combined with fludarabine and cyclophosphamide for lymphodepletion. This treatment is designed to target and manage immune-mediated diseases.

Study Design: This is an open-label, non-randomized, multi-center, multi-cohort study with a single-group intervention model. There is no masking, and the primary purpose is treatment, focusing on assessing the therapy’s safety and tolerability.

Study Timeline: The study began on December 4, 2024, with the latest update submitted on August 18, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status, indicating active research and potential upcoming results.

Market Implications: This study’s progress could positively impact Nkarta, Inc.’s stock performance by showcasing their commitment to innovative therapies. As the study advances, investor sentiment may improve, especially if preliminary results are promising. Competitors in the CAR NK cell therapy space will be closely monitoring these developments, as successful outcomes could shift market dynamics.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.